Brainscape's Knowledge GenomeTM

Browse over 1 million classes created by top students, professors, publishers, and experts.


See full index

Oncology Boards > Melanoma > Flashcards

Melanoma Flashcards

1
Q

What breeds of dog is OMM most commonly diagnosed?

A

Scotties, goldens, Chows, poodles and dachshunds

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Canine OMM is most commonly found in what locations of the mouth in order of decreasing frequency

A

gingiva, lips, tongue and hard palate

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

WHat are the primary factors that determine the biologic behavior of an OMM in dogs

A

Site, Size, Stage and histo parameters

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

What cocktail of IHC Abs are used to diagnose melanoma

A

PNL2, tyrosinase, Melan A and S-100

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

BRAF is frequently mutated in which form of human melanoma?

A

Commonly mutated in cutaneous but not in oral (also uncommon for BRAF mutations in OMMs in dogs)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

What IHC marker can more reliably predict potential malignant behavior compared to classical histology for cutaneous melanoma?

A

Ki67 (also prognostic in OMM)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

What is the MST of dogs with melanoma of the digit w/o LN or distant mets treated with digit amp?

A

~12mo, 1yr survival 42-57%, 2yr 11-13%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

What is the rate of metastasis at presentation for dogs with digital melanoma?

A

30-40%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

What do most dogs with digital melanoma die from?

A

Metastasis - regional or distant

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

What are the T classifications for OMM based on WHO TNM staging

A

T1 ≤2cm T2 2-4cm T3 > 4cm

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

What are the N classifications for OMM based on WHO TNM staging?

A

N0 = no regional nodes N1 = histo or cyto evidence of regional node involvement N2 = fixed nodes

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

What are the WHO TNM-based stages for OMM in dogs?

A

Stage 1 = T1N0M0 2 = T2N0M0 3 = T2N1M0 or T3N0M0 4 = Any T, Any N and M1

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

What is the MST for dogs with stage I OMM treated with surgery

A

511-874d

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

What is the MST for dogs with stage II OMM treated with surgery

A

160-818d

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

What is the MST for dogs with stage III OMM treated with surgery

A

168-207d

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

What % of enlarged vs normal LN have mets from OMM?

A

70% of enlarged LN have mets 40% of normal LN have mets

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

What margins are generally recommended for benign cutaneous melanomas?

A

1cm skin margins, 1 fascial plane deep

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

What margins are recommended for OMM

A

2-3 cm when possible

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

Dogs with incomplete histo margins from OMM are ____ times more likely to die of tumor-related causes compared with dogs with complete excision

A

3.6x

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

Dogs with OMM located where in the mouth are 4.3x more likely to die of tumor-related causes

A

Caudal to PM3 (compared to those rostral to PM3)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

What is the radiosensitivity melanom

A

Generally radioresistant –> need higher dose/fx to achieve local control

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

What is the overall response rate to RT for melanoma? PR vs. CR?

A

Overall 82-94% PR 25-67% CR 19-69%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

What is the PFS for dogs treated with RT for gross disease melanoma?

A

3.6-8.6mo

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
24
Q

What is the ORR and MST for cats with OMM treated with RT?

A

ORR = 60% (1 CR 2 PRs/5 cats) MST 146d

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
25
Q

Does adding chemotherapy to RT improve outcomes for dogs with OMM?

A

No based on the largest study; may have a role as a chemosensitizer (low rate of recurrence 15% with cisplat or carbo)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
26
Q

For dogs treated for OMM with surgery + carbo +/- RT, what was the MST? How did RT influence this?

A

MST for sx/chemo/RT 440d vs. sx/chemo 387d (not stat sig), but lower rate of local recurrence for RT group (27% vs. 67%)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
27
Q

What was the difference in TTP and MST for dogs treated with RT alone vs. RT + temozolomide

A

PFS sig shorter for RT alone (110d vs. 205d), MST numerically different but not stat sig (RT alone 192d vs. 402d w/ chemo+RT)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
28
Q

When using the WHO TNM staging system, what is the PFS for OMM treated with 12x4Gy MWF RT protocol based on T?

A

T1 PFS 11.3mo T2 6.0 T3 6.7mo

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
29
Q

Bony involvement has been reported in up to _____% of dogs with melanoma

A

92%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
30
Q

What is the ORR for dogs with measurable malignant melanoma to carbo? vs. cisplat + piroxicam

A

Carbo: 28% Cisplat + piroxicam: 18%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
31
Q

What happens after intradermal or intramuscular injection of a DNA vaccine (ex: melanoma vs)

A

APCs (dendritic cells) present the Ag on MHC

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
32
Q

Collectively, the melanoma vx literature has showed what?

A
  1. It’s safe 2. It leads to development of antityrosinase Ab and T cells 3. potentially therapeutic 4. needs to be further investigated in adjuvant, minimal disease phase II setting
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
33
Q

Other than the oncept vaccine, what other vaccine has been shown to be potentially beneficial for canine OMM

A

CSPG4 vx MST and median DFI longer for vx group

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
34
Q

What are the T classifications for digital melanoma based on WHO TNM staging

A

T1: <2cm + superficial or exophytic T2 = 2-5cm with minimal invasion T3 = >5cm or invading the SQ T4 = invading into fascia or bone

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
35
Q

What are the stages of digital melanoma in dogs based on WHO TNM staging

A

1 = T1N0M0 2 = T2N0M0 3 = T2N1M0, T3 or T4 N0 or N1 M0 4 = Any T, any N, M1

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
36
Q

What was the MST for dogs treated with digit amp + oncept based on digital melanoma stage?

A

stage 1 = >952d 2 = >1093d 3 = 321d 4 = 76d ** Oncept sig improved outcomes compared to historic controls**

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
37
Q

What was the MST for dogs treated with digit amp + oncept for digital melanoma w/ vs. w/o mets

A

W/mets = 105d w/o = 533d

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
38
Q

What was the mOST for dogs with malignant melanomas of the haired skin treated with surgery? (Laver can Vet J 2018)

A

1363d

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
39
Q

What were prognostic factors identified for dogs with malignant melanomas of haired skin treated with surgery? (Laver Can Vet J 2018)

A

MI >20, age >9.4

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
40
Q

What was the postop rate of metastasis and local recurrence for dogs with malignant melanoma of haired skin treated with surgery? (Laver Can Vet J 2018)

A

Met rate 22%, local recurrence 8%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
41
Q

What was the sensitivity and specificity of identifying amelanotic OMM with cytology vs. cytology + ICC? What ICC markers were used? (Prezezdzieck Vet Clin Path 2015)

A

ICC for cytokeratin, vimentin and Melan A Cyto alone: sens 66.7%, spec 85.7% Cyto + ICC = both 100%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
42
Q

What was the staining pattern for RACK1 for melanomas vs melanocytomas? (Campagne Vet Path 2013)

A

All stained positive Melanomas all homogenous Melanocytomas all heterogenous

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
43
Q

What is the sensitivity and specificity of PNL2 + Melan-A + TRP1 and TRP2 in identifying amelanotic OMM? (Smedley Vet Path 2011)

A

100% specific, 93.3% sensitive

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
44
Q

What marker can help differentiate STS from amelanotic OMM given that 80% of STS were found to be positive for this and all OMM were negative (Smedley Vet Path 2011)

A

CD34

45
Q

Decalcification of tissues can decrease staining for ____ but not ______ for melanoma IHC. (Ramos-Vara Vet Path 2011)

A

PNL2 and MelanA but does not affect tyrosinase

46
Q

Tyrosinase expression was found in ___% of canine and equine melanocytic tumors and in _____% of non-melanomas. This (was/was not) correlated with tumor pigmentation. (Phillips AJVR 2012) **Committee member**

A

Tyrosinase expressed in all melanomas, no expression in non-melanomas tyrosinase expression not correlated with tumor pigmentation

47
Q

Cytoplasmic staining of Gal3 was correlated with what in OMM? (Vargas J Comp Path 2019)

A

Better survival and BLC2 intensity

48
Q

What staining pattern of Galectin-3 (Gal3) was correlated with a worse outcome in dogs with OMM? What else was associated with a worse outcome? (Vargas J Comp Path 2019)

A

Nuclear Gal-3 staining High nuclear atypia

49
Q

T/F: the Clark level (anatomical level of invasion through the layers of the dermis) was found to be prognostic for cutaneous melanoma while tumor thickness was not. (Silvestri Vet Path 2018)

A

F - thickness was correlated with a shorter OST and DFS vs. Clark was NOT prognostic

50
Q

Co-expression of _____ and a Ki67> _____ were both associated with a worse prognosis in dogs with OMM (Iussich VCO 2016)

A

co expression of PDGFR alpha and beta Ki67 >19.5

51
Q

What was significantly associated with PFI and ST for dogs with OMM treated with surgery +/-adjuvant therapy (Tuohy JAVMA 2014)

A

Receiving adjuvant treatment (more likely to have disease progression if they got it), presence of metastatic disease at dx, higher tumor stage (III or IV), increased tumor size (>3cm) and sexually intact females

52
Q

What was the median PFI and MST for dogs with OMM treated with surgery alone? (Tuohy JAVMA 2015)

A

PFI >567d, MST 874d –> dogs that have completely resected melanomas can have long PFI and MST with surgery alone

53
Q

What was prognostic for dogs with melanomas and c-kit expression? (Newman Vet Path 2012)

A

MST significantly longer for melanomas with any c-kit positivity vs. those without (100% of benign melanocytiic tumors expressed kit, only 9.8% of malignant did)

54
Q

What was the relationship found between angiogenesis/tumor vascularization and canine melanoma? (Cuitino 2012 J Comp Path)

A

Tumor vascularization higher in melanomas (higher microvessel density and endothelial area) than melanocytomas but not prognostic for outcome

55
Q

What MI cutoffs are prognostic for oral/lip melanoma and cutaneous/digit melanoma in dogs? (Smedley Vet Path 2011)

A

Oral/lip: ≥4 = poor prognosis Cutaneous/digit: ≥ 3 = poor prognosis

56
Q

What ki67 cutoff has been found to be prognostic for oral/lip melanoma vs. cutaneous/digit melanoma in dogs? (Smedley Vet Path 2011)

A

Oral/lip ≥19.5 = poor prognosis Digit/cutaneous ≥15% = poor prognosis

57
Q

What % nuclear atypia (counted per 200 cells) has been found to be prognostic for oral/lip melanoma vs. cutaneous/digit melanoma in dogs? (Smedley Vet Path 2011)

A

Oral/lip ≥30% poor prog Cutaneous/digit: ≥20% poor prog

58
Q

What change in snRNA and snoRNA was found to be similar between human and cutaneous melanoma cell lines? (Rahman VCO 2019)

A

Upregulation of small nuclear RNA (snRNA) U1 and decreased small nucleolar RNA (snoRNA) RA24

59
Q

Somatic focal amplifications on chromosome _____ in canine oral melanoma was associated with ______ and a ______ prognosis (Prouteau VCO 2019)

A

Chromosome 30 Amelanomic phenotype, high MI and poor prognosis

60
Q

Which cyclin was found in 70% of canine OMM and was correlated with Ki67? (Zamboni VCO 2019)

A

Cyclin D1

61
Q

What is pevondedistat and what does it cause? (Wood VCO 2019)

A

selective inhibitor of NEDD8-activating enzyme DNA re-replication, S phase arrest, DNA damage and apoptosis

62
Q

What did pevondedistat do to canine melanoma cell lines? ( Wood vco 2019)

A

Dose and time dependent reduction in cell viability - promoted apoptosis and inhibition of cell growth (some lines resistant though)

63
Q

CD20 Tumor-infiltrating lymphocytes were found to be associated with what in canine melanocytic tumors? (Porcellato VCO 2019)

A

Mitotic count, cellular pleomorphism, % pigmented cells high infiltration assciated with tumor related death, presence of mets/recurrence, shorter overall DFS

64
Q

What affect did GD3-based immunotherapy have on myeloid-derived suppressor cells in dogs with melanoma? (Hutchinson Vet Immuno 2019)

A

MDCS decreased significantly

65
Q

What cytokines were found to be significantly elevated in canine melanoma compared to controls? (Hutchinson Vet Immuno 2019)

A

IL10, MCP1 (monocyte chemoattractant protein-1)

66
Q

What was the effect of high-dose ascorbate on canine melanoma cell lines? (Shin VCO 2018)

A

All four lines reduced viability in concentration-dependent manner induced apoptosis via activation of Bax

67
Q

Melanomas with a higher number of FoxP3/hpf had a higher/lower risk of death? (Porcellato Vet Path 2018)

A

Higher

68
Q

T/F: the number of IDO positive cells/hpf in canine melanoma was found to be an independent prognostic indicator. (Porcellato Vet Path 2018)

A

T

69
Q

T/F altered expression of BAP1 (deubiquitylase) can be used as a prognositic marker in both people and dogs (Jama J Comp Path 2018)

A

F - not good in dogs People yes (loss of nuclear BAP-1 is prognostic) - this study showed 100% of dog melanomas were positive for nuclear BAP-1 meaning it does not have same prognostic value in dogs.

70
Q

What % of feline non-ocular amelanotic melanomas stained positively for Melan A? What about S100? (Sabattini BMC 2018)

A

48% for Melan A; 95% for S100

71
Q

What was associated with a poor outcome in cats with non-ocular melanocytic tumors? (Sabattini BMC 2018)

A

Tumor histotype (spindle, balloon and signet ring cell) and treatment

72
Q

What was significantly higher in feline melanomas that were spindle histotype, in tumours lacking junctional activity and in poorly-pigmented tumours? (Sabattini BMC 2018)

A

mi and Ki67

73
Q

Canine primary OMM cells expressed what two markers indicating a shift to mesenchymal phenotype/EMT? (Shmid VCO 2019)

A

MMP2 and vimentin

74
Q

What is IQGAP1 and how does it related to melanoma? (Lee Plosone 2017)

A

Signaling scaffold that regulates oncogenic ERK1/2 MAPK signaling in human ras and raf driven cancers

IQGAP1 expressed in human and canine melanoma cell lines

Deletion of IQGAP1 = reduced MAPK activation; blocking peptides reduced proliferation in vitro

75
Q

Altered expression of what MMPs correlated with clinicopathologic features in canine oral cancers? What markers were associated with early stage oral tumors? (Pisamai Res Vet Sci 2017)

A

MMPs 7 &2 correlated with path

TIMP1 and MMP14 associated with early stage tumors

76
Q

Early stage OMM had notable MMP____ expression vs. late-stage OMM had MMP ____ expression (Pisamai Res Vet Sci 2017)

A

Early: MMP14

Late: MMP7

77
Q

What is bortezomib? (Ito Vet J 2013)

A

Boric acid analog that inhibits 26s proteasome - may inhibit NFkB signaling by preventing degredation of the IKappaB inhibitor

Approved for use in MM and mantle LSA in humans

78
Q

What was the effect of Bortezomib in canine malignant melanoma cell lines? (Ito Vet J 2013)

A

Potent growth inhibition

IKappaB levels increased

79
Q

Was MDR1-P-glycoprotein expression higher in canine cutaneous or oral melanoma? (Finotello VCO 2017)

A

Higher in OMM (100%) vs. cutaneous (66.6%

PgP may be one reason for chemo resistance in OMM

80
Q

What was the objective tumor response rate for a canine-chimerized anti-PDL1 mAb (c4G12) used in OMM or undifferentiated sarcoma? (Maekawa Sci Rep 2017)

A

OMM: 14% (1/7)

Anaplastic sarcoma 50%

81
Q

What canine tumor types were found to express PDL1 (cell lines used) (Maekawa PLOS one 2016)

A

OMM, OSA, HSA, Grade III MCT, mammary adenocarcinoma, prostatic carcinoma

82
Q

How does PDL1 aid in development of cancers? What has blocking it been shown to do in vitro (primarily with OMM cell lines)? (Maekawa PLOS + Nemoto Vet immuno 2018)

A

PD1 = costimulatory receptor with immunosuppressive activity - inhibits function of cytotoxic tell cells –> dysfunction of tumor specific lymphs –> immune evasion

Blocking shows increased IFN-gamma levels (produced by T cells)

83
Q

What was the effect of celecocib on canine melanoma cell lines? (Seo 2014)

A

anti-tumor effect on two cell lines via G1-S cell cycle arrest

84
Q

T/F: Wnt/B catenin signaling is common in canine malignant melanoma? (Chon 2013)

A

F - rare in OMM and melanoma cell lines

another study (Han 2013) did show loss of membrane e-cadherin/b catenin complex in both skin and oral melanomas, so b-catenin may be involved still

85
Q

What 4 genes had increased expression in canine uveal melanomas that metastasized? (also found in human uveal melanomas that met) (Malho JSAP 2013)

A

HTR2B, FXR1, LTA4H, CDH1

86
Q

COX-2 expression was highest in canine melanomas with what characteristics? (Martinez Vet Path 2011)

A

Moderate to high in 88% of OMM and in 73% of tumors with MI ≥3

Low to absent in 75% of cutaneous melanomas and 81% of melanomas with MI < 3

**correlated with survival at 1 yr - high cox2 = 16.7% alive vs. no cox-2 100% alive**

87
Q

Which MMP was overexpressed in malignant melanoma compared to melanocytoma? (Docampo AJVR 2011)

A

MMP 9 (no sig differences in MMP-2 and MTI-MMP)

88
Q

What is Fascin-1 and what was its relationship with canine melanoma? (Yamada VCO 2011)

A

actin bundling protein - increased expression correlates with aggressive behavior in human melanoma

High staining correlated with significant decrease in survival for canine melanomas (melanomas also had higher staining (98%) than melanocytomas (59%)

89
Q

What is CSPG4 and how has it been used in the treatment of dogs with OMM? (Piras VCO 2017, Riccardo 2014)

A

Human chondroitin sulfate proteoglycan-4 used for electrovaccination in dogs

Possible survival benefit (longer DFI and OS in 2014 study and longer DFI and OS in dogs <20kg in 2017 study); lower rate of pulm mets in 2017 study for vx dogs (40%) vs. unvx dogs (80%)

90
Q

What was the clinical response rate to the oncept vaccine in UK dogs with macroscopic melanoma? (Verganti JSAP 2017)

A

8/13 (61.5%) but half had other treatment too (variety of chemo/RT)

91
Q

What was the PFS and MST for dogs with OMM treated with a combination of surgery + Oncept? (Treggiari J Vet Med Sci 2016). What % of dogs in this study didn’t finish the induction phase due to progressive disease?

A

PFS 160d, MST 335d

20% didn’t finish

92
Q

What was the MST of of dogs with stage II/III OMM with no gross disease treated with the oncept vaccine? How did this compare to historic controls? (Grosenbaugh AJVR 2011)

A

MST not reached for vx group vs. 324d for controls

MST may be longer compared to Treggiari 2016 paper due to different population or poor locoregional control in the 2016 paper)

93
Q

What was the rate of AEs to the oncept vx in cats? (Sarbu JFMS 2015)

A

11.4% (all grade 1-2)

pain on admin, brief mm fasiciulation, transient inappetence, depression, nausea, mild increase in pigmentation at injection site

94
Q

What was found in the Ottnod VCO 2013 paper about the oncept vaccine and canine OMM?

A

No difference in PFS or MST in vx vs. nonvx; nonvx had better DFI than vx

these dogs were treated with a mix of surgery or surgery + RT in addition to the melanoma vx

95
Q

What is NHS-IL12 and what were the AEs in dogs treated with it for malignant melanoma? (Paoloni PLOS 2015) **Committee member**

A

NHS-IL12 = immunocytokine consisting of antibody targeting necrotic tumor regions linked to IL-12 (IL12 given by itself usually causes unacceptable tox)

AEs of NHS-IL12 = thrombocytopenia, liver enzyme elevation, fever and vasculitis –> narrow therapeutic window found

96
Q

What were the findings of the oncept phase I trial (Bergman clin cancer res 2003)

A

1 dog with lung mets had CR for 329d

2 stage IV had longer term survival (421 and 588+)

2 dogs with local control stage 2 and 3 had long term survival (501 and 496)

overall MST = 389d

97
Q

What is liporaxel and what was its effect on canine melanoma in vitro and in a mouse xenograft model? (Yang VCO 2019)

A

oral paclitaxel

in vitro - antiproliferative effect + mediated cell cycle arrest

mouse model - decreased tumor size by ~30% compared to controls

98
Q

What was the effect of metronomic cytoxan + piroxicam on canine OMM in a mouse xenograft model? (Choisunirachon 2015)

A

combination significantly lowered microvessel density and VEGF levels –> ctx or piroxicam alone did not

99
Q

What was the MST for dogs with OMM treated with surgery alone vs. surgery + adjuvant therapy (chemo, vaccine) (Boston JAVMA 2014)

A

Surgery alone 335d, adjuvant 352d - not stat different

100
Q

What was the result of carboplatin chemotherapy for dogs with malignant melanoma with or without surgery? (Brockley New Zealand Vet J 2013)

A

No benefit in locoregional control in sx + chemo group

gross disease 3/11 responded (27%), those that did respond had a survival benefit (987d vs. 147d)

Take home: carbo not very effective for OMM

101
Q

What was the ORR to carboplatin for dogs with malignant melanoma (Rassnick JAVMA 2001)

A

28%

102
Q

Was there a benefit to adding temozolomide to RT (6Gy x5) for treatment of dogs with measurable melanoma? (Cancedda VCO 2016)

A

Yes - not different response rate but median time to progression longer for temozolomide group (205d vs. 110d) and MST numerically (but not stat sig) for temozolomide group (401d vs. 192)

103
Q

What was the local response to RT in dogs with OMM and the median time to first event (progression) and MST? (Proulx VRU 2003)

A

Response: CR 51%, PR 31%, 16% SD, 1% PD

Metian time to first event: 5mo

MST 7mo - best for dogs without risk factors

104
Q

T/F - The addition ofcarboplatin has been shown to benefit dogs with OMM treated with RT compared to dogs treated with RT alone.

A

False - none of the RT studies have found a benefit in adding carbo

105
Q

What is the most common site for ocular melanoma in the dog?

A

Limbal (20-50% of ocular melanomas)

106
Q

How do uveal melanomas behave in dogs vs. cats?

A

typically low metastatic rate in dogs, only treat w/ enuc if causing problems (ex. glaucoma or uveitis)

Cats: anterior uveal melanoma = most common ocular tumor in cats, higher met rate (60%)

107
Q

What was the response to synthetic microRNA-205 given to dogs via intratumoral injection for malignant melanoma? (Yoshikawa VOC 2019)

A

5 CR, 3 SD and 2 PD

108
Q

Gene expression analysis of ocular melanomas in cats showed significant upregulation of _____ and down regulation of ____

A

up: KIT and LTA4H
down: BRAF (and others that I am never going to remember)

109
Q

What % of LN diagnosis changed when comparing cyto and histo for regional LN staging in dogs with melanoma? (Grimes vet path 2017)

A

47% (15 cases, 14 of which were considered metastatic and changed to negative)

take home: agreement b/w cyto and histo for LN is poor

Oncology Boards (26 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2024 Bold Learning Solutions. Terms and Conditions